PT - JOURNAL ARTICLE AU - Breznik, Jessica A. AU - Zhang, Ali AU - Huynh, Angela AU - Miller, Matthew S. AU - Nazy, Ishac AU - Bowdish, Dawn M. E. AU - Costa, Andrew P. AU - for the COVID-in-LTC Study Group TI - Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents AID - 10.1101/2021.08.17.21262152 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.17.21262152 4099 - http://medrxiv.org/content/early/2021/08/19/2021.08.17.21262152.short 4100 - http://medrxiv.org/content/early/2021/08/19/2021.08.17.21262152.full AB - Nursing home residents often fail to mount robust responses to vaccinations and recent reports of breakthrough infections, particularly from variants of concern, raise questions about whether vaccination regimens elicit a sufficient humoral immune response or if booster doses are warranted. We examined SARS-CoV-2 antibody levels and neutralizing capacity in nursing home residents 3-5 months after 2 doses of mRNA-1273 or BNT163b2 vaccination as per recommended schedules.Nursing home residents were recruited from eight long-term care homes in Ontario, Canada, between March and July 2021. Antibody levels and neutralization capacity from a previously published convalescent cohort were used as a comparator. Serum SARS-CoV-2 IgA/G/M against spike (S) protein and its receptor-binding domain (RBD) were measured by validated ELISA, with assay cut-off at the mean and 3 standard deviations of a pre-COVID-19 population from the same geographic region. Antibody neutralization was measured against the wild-type strain of SARS-CoV-2 and the beta variant of concern (B.1.351).No neutralizing antibodies were detected in ∼20% of residents to the wild-type virus (30/155; 19%) or beta variant (27/134; 20%). Residents that received BNT163b2 had a ∼4-fold reduction in neutralization to the wild-type strain, and a ∼2-fold reduction in neutralization to the beta variant relative to those who received mRNA-1273.Current mRNA SARS-CoV-2 vaccine regimens may not have equivalent efficacy in nursing home residents. Our findings imply that differences in the humoral immune response may contribute to breakthrough infections, and suggest that consideration of the type of vaccine administered to older adults will have a positive impact on the generation of protective immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by a grant from Canadian COVID-19 Immunity Task Force and Public Health Agency of Canada awarded to Costa and Bowdish. Bowdish is the Canada Research Chair in Aging & Immunity. Costa is the Schlegel Chair in Clinical Epidemiology and Aging. Funding support for this work was provided by grants from the Ontario Research Fund, COVID-19 Rapid Research Fund, and by the Canadian COVID-19 Immunity Task Force awarded to Nazy. Miller is supported, in part, by an Ontario Early Researcher Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All protocols were approved by the Hamilton Integrated Research Ethics Board (HiREB), and informed consent was obtained.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not available without prior approval from the Hamilton Integrated Research Ethics Board (HiREB).